Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SARS-CoV-2 inactivated vaccine (Vero cell) + quadrivalent influenza vaccine
- Development stage
- Unknown
- Lead developer
- Sinovac Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
SARS-CoV-2 inactivated vaccine (Vero cell) + quadrivalent influenza vaccine refers to a vaccination strategy involving the concomitant administration of an inactivated SARS-CoV-2 vaccine (specifically Sinovac's CoronaVac) and a quadrivalent inactivated influenza vaccine (IIV4). This regimen is not a single fixed-dose formulation but rather the simultaneous administration of two separate vaccines at different injection sites. Developed and studied by Sinovac Biotech, the combination aims to simplify immunization schedules and provide dual protection against COVID-19 and seasonal influenza. Clinical trials, including Phase 4 studies (NCT04801888), have demonstrated that the co-administration is safe and maintains the immunogenicity of both the SARS-CoV-2 component (targeting the spike and other viral proteins) and the four influenza strains (targeting hemagglutinin antigens of H1N1, H3N2, and two B lineages).
- Brand names
- CoronaVac
- Other names
- CoronaVac + IIV4SARS-CoV-2 inactivated vaccine + IIV4
02
Targets
SARS-CoV-2 spikeHA (Hemagglutinin)
Beyond the preview
Go deeper on SARS-CoV-2 inactivated vaccine (Vero cell) + quadrivalent influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SARS-CoV-2 inactivated vaccine (Vero cell) + quadrivalent influenza vaccine.